Equities research analysts at Canaccord Genuity Group initiated coverage on shares of Nuformix (LON:NFX – Get Free Report) in a report released on Tuesday,Digital Look reports. The brokerage set a “buy” rating and a GBX 293 ($3.81) price target on the stock.
Nuformix Stock Up 36.0 %
Shares of LON:NFX opened at GBX 0.10 ($0.00) on Tuesday. The business has a fifty day moving average of GBX 0.08 and a two-hundred day moving average of GBX 0.07. The stock has a market cap of £1.26 million, a P/E ratio of -3.10 and a beta of 1.22. Nuformix has a 52-week low of GBX 0.04 ($0.00) and a 52-week high of GBX 0.30 ($0.00).
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- 3 Grocery Stocks That Are Proving They Are Still Essential
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Alphabet’s Officially In A Bear Market—Time To Buy?
- How to Invest in Small Cap Stocks
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
